Tuberculous meningitis: Difference between revisions

From IDWiki
m (Text replacement - "== Clinical Presentation" to "== Clinical Manifestations")
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
* Meningeal infection by ''[[Mycobacterium tuberculosis]]''
+
*Meningeal infection by ''[[Mycobacterium tuberculosis]]''
* High mortality, often needs empiric treatment even before confirmed diagnosis
+
*High mortality, often needs empiric treatment even before confirmed diagnosis
   
== Background ==
+
==Background==
=== Classification ===
+
===Classification===
* '''Stage 1:''' normal level of consciousness, no focal neurological deficits
 
* '''Stage 2:''' decreased level of consciousness, significant focal neurological deficits
 
* '''Stage 3:''' seizures, comatose
 
   
  +
*'''Stage 1:''' normal level of consciousness, no focal neurological deficits
=== Epidemiology ===
 
  +
*'''Stage 2:''' decreased level of consciousness, significant focal neurological deficits
* About 1% of TB cases in Canada
 
  +
*'''Stage 3:''' seizures, comatose
   
  +
===Epidemiology===
=== Differential Diagnosis ===
 
* Fungal meningitis
 
* Sarcoidosis
 
* Neoplasm
 
   
  +
*About 1% of TB cases in Canada
=== Risk Factors ===
 
* Young
 
* Female
 
* Originally from endemic country
 
* Previous TB
 
   
  +
===Risk Factors===
== Clinical Manifestations ==
 
=== History ===
 
   
  +
*Young
* Prodrome (1-3 weeks)
 
  +
*Female
** Personality changes
 
  +
*Originally from endemic country
** Low-grade fever
 
  +
*Previous TB
** Malaise
 
** Weight loss
 
** Gradual onset of worsening headache
 
* Headache
 
* Fevers
 
* Vomiting
 
* Confusion
 
* Personality changes
 
* Photophobia (only 5-10%)
 
* Seizures
 
   
  +
==Clinical Manifestations==
=== Physical Exam ===
 
  +
===History===
* Meningeal symptoms
 
* Fevers
 
* Vomiting
 
* Meningismus
 
* Focal neurological deficits
 
** Cranial nerve palsies in VI, III, and IV
 
** Hemiplegia, paraplegia
 
** Urinary retention
 
* Confusion, coma
 
   
  +
*Prodrome (1-3 weeks)
== Investigations ==
 
  +
**Personality changes
* Lumbar puncture
 
  +
**Low-grade fever
** Increased lymphocytes, decreased glucose, and increased protein
 
  +
**Malaise
** Need 3-5mL of CSF for culture
 
  +
**Weight loss
** May need serial LPs
 
  +
**Gradual onset of worsening headache
* CT head
 
  +
*Headache
  +
*Fevers
  +
*Vomiting
  +
*Confusion
  +
*Personality changes
  +
*Photophobia (only 5-10%)
  +
*Seizures
   
  +
===Physical Exam===
== Management ==
 
  +
* Rule out neoplasm and fungus, then start empiric treatment
 
  +
*Meningeal symptoms
* HIV test (delay antiretrovirals by 8 weeks, though)
 
  +
*Fevers
* Standard HREZ x2mo then HR x7-10mo
 
  +
*Vomiting
** Can replace ethambutol with a fluoroquinolone
 
  +
*Meningismus
* Dexamethasone 3mg po qid x2wk then taper over 6-8wks
 
  +
*Focal neurological deficits
** High risk of IRIS
 
  +
**Cranial nerve palsies in VI, III, and IV
  +
**Hemiplegia, paraplegia
  +
**Urinary retention
  +
*Confusion, coma
  +
  +
===Thwaites Index===
  +
  +
*Used to differentiate bacterial from tuberculous meningitis in adults before results of CSF culture are available[[CiteRef::thwaites2002di]]
  +
*Tuberculous more likely if score ≤4; bacterial more likely if score ≥5
  +
**Sensitivity 86% and specificity 79%
   
 
{| class="wikitable"
 
{| class="wikitable"
  +
!Item
! Drug
 
  +
!Score
! Dose
 
! Duration
 
! CSF penetration
 
 
|-
 
|-
  +
|Age ≥36 years
| [[Rifampin]]
 
  +
| +2
| 10 mg/kg (max 600 mg)
 
| 12 months
 
| 10-20%
 
 
|-
 
|-
  +
|Blood WBC ≥15
| [[Isoniazid]]
 
  +
| +4
| 5 mg/kg (max 300 mg)
 
| 12 months
 
| 80-90%
 
 
|-
 
|-
  +
|≥6 days of illness
| [[Pyrazinamide]]
 
  +
| -5
| 25 mg/kg
 
| 2 months
 
| 90-100%
 
 
|-
 
|-
  +
|CSF WBC ≥900x10<sup>3</sup>
| [[Ethambutol]]
 
  +
| +3
| 15 mg/kg
 
| 2 months
 
| 20-30%
 
 
|-
 
|-
  +
|CSF % PMN ≥75
! colspan=4 | Second-line treatments
 
  +
| +4
  +
|}
  +
  +
=== Complications and Prognosis ===
  +
*Depends on stage at presentation
  +
*Mortality is high
  +
**Stage 1: 10-20%
  +
**Stage 2: 20-40%
  +
**Stage 3: 60%
  +
*Morbidity is high, with about 20% of patient being left with significant neurological sequelae
  +
**Mental retardation, psychiatric disorders, [[seizure]], blindness, deafness, ophthalmoplegia, hemiparesis
  +
  +
==Differential Diagnosis==
  +
  +
*[[Fungal meningitis]]
  +
*[[Sarcoidosis]]
  +
*[[Neoplasm]]
  +
*Other causes of [[chronic meningitis]]
  +
  +
==Investigations==
  +
  +
*Lumbar puncture
  +
**Increased lymphocytes, decreased glucose, and increased protein
  +
**Need 3-5mL of CSF for culture
  +
**May need serial LPs
  +
*CT head
  +
  +
==Diagnosis==
  +
  +
*Gold standard is mycobacterial culture (71% sensitive, 100% specific)
  +
**Sensitivity increases with volume and number of samples
  +
*Microscopy for acid-fast bacilli is 20-80% sensitive and 100% specific
  +
*PCR is 85-95% sensitive and 98% specific
  +
**Used to confirm but not exclude the diagnosis
  +
  +
==Management==
  +
  +
*Rule out neoplasm and fungus, then start empiric treatment
  +
*[[HIV]] test (delay [[HIV medications|antiretrovirals]] by 8 weeks, though)
  +
*Standard HREZ x2mo then HR x7-10mo
  +
**Can replace [[ethambutol]] with a [[fluoroquinolone]]
  +
*Adjunctive steroids for high risk of IRIS
  +
**[[Dexamethasone]] 3mg po qid x2wk then taper over 6-8wks
  +
**[[Prednisolone]] 120 mg PO daily x1wk, 90 mg x1wk, 60 mg x1wk, 30 mg x1wk, 15 mg x1wk, 5 mg x1wk
  +
  +
{| class="wikitable"
  +
!Drug
  +
!Dose
  +
!Duration
  +
!CSF penetration
 
|-
 
|-
| [[Levofloxacin]]
+
|[[Rifampin]]
| 10-15 mg/kg
+
|10 mg/kg (max 600 mg)
  +
|12 months
| Throughout treatment
 
| 70-80%
+
|10-20%
 
|-
 
|-
| [[Moxifloxacin]]
+
|[[Isoniazid]]
| 400 mg
+
|5 mg/kg (max 300 mg)
  +
|12 months
| Throughout treatment
 
| 70-80%
+
|80-90%
 
|-
 
|-
| [[Amikacin]]
+
|[[Pyrazinamide]]
| 15 mg/kg (max 1 g)
+
|25 mg/kg
  +
|2 months
| Intensive phase only
 
| 10-20%
+
|90-100%
 
|-
 
|-
| [[Kanamycin]]
+
|[[Ethambutol]]
| 15 mg/kg (max 1 g)
+
|15 mg/kg
  +
|2 months
| Intensive phase only
 
| 10-20%
+
|20-30%
 
|-
 
|-
  +
! colspan="4" |Second-line treatments
| [[Capreomycin]]
 
| 15 mg/kg (max 1 g)
 
| Intensive phase only
 
| Probably very low
 
 
|-
 
|-
  +
|[[Levofloxacin]]
| [[Ethionamide]] or [[prothionamide]]
 
| 15-20 mg/kg (max 1 g)
+
|10-15 mg/kg
| Throughout treatment
+
|Throughout treatment
| 80-90%
+
|70-80%
 
|-
 
|-
| [[Cycloserine]]
+
|[[Moxifloxacin]]
  +
|400 mg
| 10-15 mg/kg (max 1 g)
 
| Throughout treatment
+
|Throughout treatment
| 80-90%
+
|70-80%
 
|-
 
|-
| [[Linezolid]]
+
|[[Amikacin]]
  +
|15 mg/kg (max 1 g)
| 600 mg
 
  +
|Intensive phase only
| Throughout treatment
 
| 30-70%
+
|10-20%
 
|-
 
|-
  +
|[[Kanamycin]]
! colspan=4 | Other drugs with uncertain benefit
 
  +
|15 mg/kg (max 1 g)
  +
|Intensive phase only
  +
|10-20%
 
|-
 
|-
| [[Clofazimine]]
+
|[[Capreomycin]]
| 100 mg daily
+
|15 mg/kg (max 1 g)
  +
|Intensive phase only
|
 
| Probably low
+
|Probably very low
 
|-
 
|-
  +
|[[Ethionamide]] or [[prothionamide]]
| [[p-aminosalicylic acid]]
 
| 200-300 mg/kg
+
|15-20 mg/kg (max 1 g)
  +
|Throughout treatment
  +
|80-90%
  +
|-
  +
|[[Cycloserine]]
  +
|10-15 mg/kg (max 1 g)
  +
|Throughout treatment
  +
|80-90%
  +
|-
  +
|[[Linezolid]]
  +
|600 mg
  +
|Throughout treatment
  +
|30-70%
  +
|-
  +
! colspan="4" |Other drugs with uncertain benefit
  +
|-
  +
|[[Clofazimine]]
  +
|100 mg daily
 
|
 
|
| Probably very low
+
|Probably low
 
|-
 
|-
  +
|[[p-aminosalicylic acid]]
| [[Bedaquiline]]
 
  +
|200-300 mg/kg
|
 
 
|
 
|
| Probably very low
+
|Probably very low
 
|-
 
|-
| [[Delamanid]]
+
|[[Bedaquiline]]
 
|
 
|
 
|
 
|
  +
|Probably very low
| No data
 
  +
|-
  +
|[[Delamanid]]
  +
|
  +
|
  +
|No data
 
|}
 
|}
 
== Prognosis ==
 
* Depends on stage at presentation
 
* Mortality is high
 
** Stage 1: 10-20%
 
** Stage 2: 20-40%
 
** Stage 3: 60%
 
* Morbidity is high, with about 20% of patient being left with significant neurological sequelae
 
** Mental retardation
 
** Psychiatric disorders
 
** Seizures
 
** Blindness
 
** Deafness
 
** Ophthalmoplegia
 
** Hemiparesis
 
   
 
==Further Reading==
 
==Further Reading==
  +
* Treatment of Tuberculous Meningitis and Its Complications in Adults. ''Curr Treat Options Neurol''. 2018;20(3):5. doi: [https://doi.org/10.1007/s11940-018-0490-9 10.1007/s11940-018-0490-9]
 
  +
*Treatment of Tuberculous Meningitis and Its Complications in Adults. ''Curr Treat Options Neurol''. 2018;20(3):5. doi: [https://doi.org/10.1007/s11940-018-0490-9 10.1007/s11940-018-0490-9]
   
 
[[Category:Tuberculosis]]
 
[[Category:Tuberculosis]]

Latest revision as of 11:47, 13 March 2023

Background

Classification

  • Stage 1: normal level of consciousness, no focal neurological deficits
  • Stage 2: decreased level of consciousness, significant focal neurological deficits
  • Stage 3: seizures, comatose

Epidemiology

  • About 1% of TB cases in Canada

Risk Factors

  • Young
  • Female
  • Originally from endemic country
  • Previous TB

Clinical Manifestations

History

  • Prodrome (1-3 weeks)
    • Personality changes
    • Low-grade fever
    • Malaise
    • Weight loss
    • Gradual onset of worsening headache
  • Headache
  • Fevers
  • Vomiting
  • Confusion
  • Personality changes
  • Photophobia (only 5-10%)
  • Seizures

Physical Exam

  • Meningeal symptoms
  • Fevers
  • Vomiting
  • Meningismus
  • Focal neurological deficits
    • Cranial nerve palsies in VI, III, and IV
    • Hemiplegia, paraplegia
    • Urinary retention
  • Confusion, coma

Thwaites Index

  • Used to differentiate bacterial from tuberculous meningitis in adults before results of CSF culture are available1
  • Tuberculous more likely if score ≤4; bacterial more likely if score ≥5
    • Sensitivity 86% and specificity 79%
Item Score
Age ≥36 years +2
Blood WBC ≥15 +4
≥6 days of illness -5
CSF WBC ≥900x103 +3
CSF % PMN ≥75 +4

Complications and Prognosis

  • Depends on stage at presentation
  • Mortality is high
    • Stage 1: 10-20%
    • Stage 2: 20-40%
    • Stage 3: 60%
  • Morbidity is high, with about 20% of patient being left with significant neurological sequelae
    • Mental retardation, psychiatric disorders, seizure, blindness, deafness, ophthalmoplegia, hemiparesis

Differential Diagnosis

Investigations

  • Lumbar puncture
    • Increased lymphocytes, decreased glucose, and increased protein
    • Need 3-5mL of CSF for culture
    • May need serial LPs
  • CT head

Diagnosis

  • Gold standard is mycobacterial culture (71% sensitive, 100% specific)
    • Sensitivity increases with volume and number of samples
  • Microscopy for acid-fast bacilli is 20-80% sensitive and 100% specific
  • PCR is 85-95% sensitive and 98% specific
    • Used to confirm but not exclude the diagnosis

Management

  • Rule out neoplasm and fungus, then start empiric treatment
  • HIV test (delay antiretrovirals by 8 weeks, though)
  • Standard HREZ x2mo then HR x7-10mo
  • Adjunctive steroids for high risk of IRIS
    • Dexamethasone 3mg po qid x2wk then taper over 6-8wks
    • Prednisolone 120 mg PO daily x1wk, 90 mg x1wk, 60 mg x1wk, 30 mg x1wk, 15 mg x1wk, 5 mg x1wk
Drug Dose Duration CSF penetration
Rifampin 10 mg/kg (max 600 mg) 12 months 10-20%
Isoniazid 5 mg/kg (max 300 mg) 12 months 80-90%
Pyrazinamide 25 mg/kg 2 months 90-100%
Ethambutol 15 mg/kg 2 months 20-30%
Second-line treatments
Levofloxacin 10-15 mg/kg Throughout treatment 70-80%
Moxifloxacin 400 mg Throughout treatment 70-80%
Amikacin 15 mg/kg (max 1 g) Intensive phase only 10-20%
Kanamycin 15 mg/kg (max 1 g) Intensive phase only 10-20%
Capreomycin 15 mg/kg (max 1 g) Intensive phase only Probably very low
Ethionamide or prothionamide 15-20 mg/kg (max 1 g) Throughout treatment 80-90%
Cycloserine 10-15 mg/kg (max 1 g) Throughout treatment 80-90%
Linezolid 600 mg Throughout treatment 30-70%
Other drugs with uncertain benefit
Clofazimine 100 mg daily Probably low
p-aminosalicylic acid 200-300 mg/kg Probably very low
Bedaquiline Probably very low
Delamanid No data

Further Reading

  • Treatment of Tuberculous Meningitis and Its Complications in Adults. Curr Treat Options Neurol. 2018;20(3):5. doi: 10.1007/s11940-018-0490-9

References

  1. ^  GE Thwaites, TTH Chau, K Stepniewska, NH Phu, LV Chuong, DX Sinh, NJ White, CM Parry, JJ Farrar. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. The Lancet. 2002;360(9342):1287-1292. doi:10.1016/s0140-6736(02)11318-3.